Cart
Account
Your Orders
Sign Out
Sign In
CRISPR editing isn’t the bottleneck anymore. Scaling it is.
Scaling isn’t just about producing more. The challenge is making CRISPR workflows reliable, reproducible, and scalable, while balancing speed, flexibility, and rigor across development. In this webinar, you’ll get a technical look at how Synthego approaches these challenges, and what that means for your CRISPR program as you progress toward clinical applications.
What you’ll learn:
- The key challenges of scaling CRISPR-based therapies
- The importance of analytical qualification and validation strategies
- Considerations for integrating gRNA and nuclease manufacturing
About the Presenter
Tyler Winick is Director of Chemistry Development at Synthego, where he has spent the past 7 years advancing scalable CRISPR manufacturing technologies for research and clinical applications. He leads teams focused on gRNA chemistry, process development, analytical qualification, and manufacturing strategies that support progression from early-stage development through GMP production.
